QuantBioMed Logo

Quantifying Biomedical Data to Advance Precision Medicine


At QuantBioMed, we are building a 3-tier AI-enabled platform to future-proof pre-clinical and early-stage clinical discoveries, ensuring they swiftly advance beyond Phase 1 Clinical Trials. By intelligently harnessing massive clinical resources, we are paving the way for AI-driven Precision Medicine.

Harnessing AI and Real World Data to Future-proof clinical research


By seamlessly integrating AI, real-world data, and cutting-edge computational biology, we are transforming the landscape of biomarker discovery— accelerating the transition from discovery to clinical impact. Our approach starts with identifying the research gaps in clinical care, followed by AI-based insights generation using big biomedical data and subsequent validation in real-world datasets obtained through our clinician-patient networks.

Capabilities


AI-powered biomarker discovery

Harnessing big multi-omics data for rapid insights.

Quick validation

Confirming in-silico discoveries using real-world clinical data.

De-risking biomarkers

Accelerating translational success with cost-efficient strategies.

Our Breakthrough Biomarker Discoveries


T2DM Subtyping

Emerging research reveals novel subtypes within Type 2 Diabetes Mellitus (T2DM), influencing disease progression and treatment responses, overlooked by traditional classifications.

Building on this research, we are developing easy-to-use biomarkers to accurately identify T2DM subtypes, enabling precise and personalized treatment strategies.

Read More

Anti-tumor Stromal Panel for Breast Cancer

Machine learning reveals key immune-modulating cell subsets in cancer playing critical roles in dictating anti-tumour responses in solid cancers.

By analyzing the complex cellular interactions within the tumour microenvironment, we are identifying previously uncharacterized cell populations influencing immune activity and therapeutic outcomes.

Read More

Adipo-aging marker

Multi-omics research identifies novel circulatory markers of adipose aging, enhancing metabolic health assessments.

Using multi-omics analysis followed by clinical and population-level validation in over 1000 samples and adipose tissues, we have discovered novel biomarkers that mark adipose ageing and metabolic dysfunction in the Indian population.

Read More

Products


iBioLabs

Beginner-friendly AI-driven discovery engine.

Read More

MetaStudio

Intermediate-level biomarker analysis and validation hub.

Read More

DeRiskBio

Advanced platform for clinical-grade biomarker de-risking.

Read More

Contact Us


Address

10 Regal Walk
Bexleyheath
London DA6 7BP
United Kingdom

Email

For collaborations & futher information reach out to [email protected]